Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $92.88 in the prior trading day, Medtronic Plc (NYSE: MDT) closed at $92.74%, Down $-0.15%. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 6.78 million shares were traded. MDT stock price reached its highest trading level at $93.28 during the session, while it also had its lowest trading level at $92.35.
Ratios:
Our goal is to gain a better understanding of MDT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.25 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.92. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.85. In the meantime, Its Debt-to-Equity ratio is 0.62 whereas as Long-Term Debt/Eq ratio is at 0.55.
On June 16, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $110.
Citigroup Upgraded its Neutral to Buy on March 04, 2025, whereas the target price for the stock was revised from $92 to $107.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 06 ’25 when Salmon Sean bought 18,378 shares for $86.81 per share.
Wall Brett A. sold 12,437 shares of MDT for $1,119,330 on Jan 24 ’25. The EVP & Pres Neuroscience now owns 40,979 shares after completing the transaction at $90.00 per share. On Jan 24 ’25, another insider, Wall Brett A., who serves as the Officer of the company, bought 12,437 shares for $90.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MDT now has a Market Capitalization of 118824050688 and an Enterprise Value of 139717492736. As of this moment, Medtronic’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.64, and their Forward P/E ratio for the next fiscal year is 15.49. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.64. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.54 while its Price-to-Book (P/B) ratio in mrq is 2.48. Its current Enterprise Value per Revenue stands at 4.166 whereas that against EBITDA is 15.332.
Stock Price History:
The Beta on a monthly basis for MDT is 0.78, which has changed by 0.1272639 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, MDT has reached a high of $96.25, while it has fallen to a 52-week low of $79.29. The 50-Day Moving Average of the stock is 4.61%, while the 200-Day Moving Average is calculated to be 6.32%.
Shares Statistics:
The stock has traded on average 7.81M shares per day over the past 3-months and 6591640 shares per day over the last 10 days, according to various share statistics. A total of 1.28B shares are outstanding, with a floating share count of 1.28B. Insiders hold about 0.18% of the company’s shares, while institutions hold 85.87% stake in the company. Shares short for MDT as of 1752537600 were 13065415 with a Short Ratio of 1.67, compared to 1749772800 on 8472735. Therefore, it implies a Short% of Shares Outstanding of 13065415 and a Short% of Float of 1.0199999.
Dividends & Splits
In the trailing 12 months, MDT’s forward annual dividend rate was 2.8, compared to 2.81 this year. Against a Trailing Annual Dividend Yield of 0.030146426The stock’s 5-year Average Dividend Yield is 2.82. The current Payout Ratio is 77.47% for MDT, which recently paid a dividend on 2025-06-27 with an ex-dividend date of 2025-06-27. Stock splits for the company last occurred on 1999-09-27 when the company split stock in a 2:1 ratio.
Earnings Estimates
The dynamic stock of Medtronic Plc (MDT) is currently being evaluated by a team of 25.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $1.32, with high estimates of $1.35 and low estimates of $1.3.
Analysts are recommending an EPS of between $5.61 and $5.5 for the fiscal current year, implying an average EPS of $5.55. EPS for the following year is $6.0, with 32.0 analysts recommending between $6.33 and $5.83.
Revenue Estimates
26 analysts predict $8.37B in revenue for the current quarter. It ranges from a high estimate of $8.48B to a low estimate of $8.32B. As of the current estimate, Medtronic Plc’s year-ago sales were $7.92BFor the next quarter, 26 analysts are estimating revenue of $8.74B. There is a high estimate of $8.84B for the next quarter, whereas the lowest estimate is $8.7B.
A total of 31 analysts have provided revenue estimates for MDT’s current fiscal year. The highest revenue estimate was $35.51B, while the lowest revenue estimate was $35.09B, resulting in an average revenue estimate of $35.28B. In the same quarter a year ago, actual revenue was $33.54BBased on 31 analysts’ estimates, the company’s revenue will be $37.14B in the next fiscal year. The high estimate is $38.1B and the low estimate is $36.76B.
